文献速递核素与放射性配体治疗肿瘤 PET/CT神经核医学

肽受体放射性核素治疗3级神经内分泌肿瘤:69例患者的安全性与生存分析

Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
PubMed 文献 · J Nucl Med · 2018-08-16

回顾性分析69例SSTR阳性G3神经内分泌肿瘤患者接受177Lu或90Y标记生长抑素类似物PRRT的长期结局,中位随访94.3个月,中位PFS 9.6个月、OS 19.9个月;PRRT耐受良好,无3/4级血液毒性及临床显著肾功能下降,无肝毒性;基线18F-FDG与SSTR分子影像可用于分层。

要点

  • 69例G3 NEN接受PRRT,中位PFS 9.6个月,中位OS 19.9个月。
  • Ki-67≤55%组中位PFS 11个月、OS 22个月;Ki-67>55%组PFS 4个月、OS 7个月。
  • SSTR PET SUVmax>15.0组中位PFS 16个月、OS 27个月,优于SUVmax≤15.0组的5个月和9个月。

核心结论

  • PRRT耐受良好、无显著不良反应,在G3 NEN中有效,临床结局有希望,尤其在Ki-67≤55%及化疗失败的患者中。
  • 基线18F-FDG联合SSTR分子影像有助于对SSTR PET/CT高摄取且18F-FDG无或低摄取(不匹配模式)的G3 NEN患者进行分层,该模式与更好的长期预后相关。

研究设计与样本

  • 回顾性分析69例SSTR阳性G3 NEN患者(男性41例,年龄28-81岁),接受177Lu或90Y标记生长抑素类似物(DOTATATE或DOTATOC)PRRT,其中22例接受放疗增敏化疗。
  • 采用Kaplan-Meier法计算PFS和OS(自PRRT开始定义),并按Ki-67≤55%与>55%进行亚组分析。
  • 疗效按RECIST 1.1及欧洲癌症研究与治疗组织分子影像标准评估,短期和长期毒性按不良事件通用术语标准5.0版通过结构化数据库(每例患者>250项)记录并回顾性分析。

主要发现

  • 肿瘤原发部位:胰腺46例、原发不明11例、中肠6例、胃3例、直肠3例。
  • 中位随访94.3个月,全组中位PFS 9.6个月、中位OS 19.9个月。
  • Ki-67≤55%组(n=53)中位PFS 11个月、中位OS 22个月;Ki-67>55%组(n=11)中位PFS 4个月、中位OS 7个月。
  • SSTR显像阳性但无18F-FDG摄取者中位PFS 24个月、中位OS 42个月。
  • SSTR PET SUVmax>15.0组与SUVmax≤15.0组中位PFS分别为16个月和5个月、中位OS分别为27个月和9个月,PFS和OS均有显著差异。

关键数值与推荐

  • G3 NEN定义为Ki-67增殖指数大于20%。
  • 疗效评估采用RECIST 1.1及欧洲癌症研究与治疗组织分子影像标准。
  • 毒性记录采用不良事件通用术语标准5.0版。
  • 亚组分析按Ki-67≤55%与>55%分层;SSTR PET按SUVmax>15.0与≤15.0分层;18F-FDG摄取按评分3或4分与0-2分分层。

临床怎么用

  • 原文未据此给出推荐。
  • PRRT耐受良好,无3级或4级血液毒性,未观察到临床显著肾功能下降,无肝毒性。
  • 基线18F-FDG联合SSTR分子影像可用于G3 NEN患者分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To date, limited data are available concerning peptide receptor radionuclide therapy (PRRT) of grade 3 (G3) neuroendocrine neoplasms (NENs) with a Ki-67 proliferation index of greater than 20%. The purpose of this study was to analyze the long-term outcome, efficacy, and safety of PRRT in patients with somatostatin receptor (SSTR)-expressing G3 NENs. Methods: A total of 69 patients (41 men; age, 28-81 y) received PRRT with 177Lu- or 90Y-labeled somatostatin analogs (DOTATATE or DOTATOC). Twenty-two patients had radiosensitizing chemotherapy. Kaplan-Meier analysis was performed to calculate progression-free survival (PFS) and overall survival (OS), defined from the start of PRRT, including a subgroup analysis for patients with a Ki-67 index of less than or equal to 55% and a Ki-67 index of greater than 55%. Treatment response was evaluated according to RECIST 1.1 as well as molecular imaging criteria (European Organization for Research and Treatment of Cancer). Short- and long-term toxicity was documented (Common Terminology Criteria for Adverse Events, v 5.0) using a structured database (comprising >250 items per patient) and retrospectively analyzed. Results: Forty-six patients had pancreatic NENs, 11 had unknown primary cancer, 6 had midgut NENs, 3 had gastric NENs, and 3 had rectal NENs. The median follow-up was 94.3 mo. The median PFS was 9.6 mo, and the median OS was 19.9 mo. For G3 NENs with a Ki-67 index of less than or equal to 55% (n = 53), the median PFS was 11 mo and the median OS was 22 mo. Patients with a Ki-67 index of greater than 55% (n = 11) had a median PFS of 4 mo and a median OS of 7 mo. For patients with positive SSTR imaging but no 18F-FDG uptake, the median PFS was 24 mo and the median OS was 42 mo. A significant difference was found for both PFS and OS, with median PFS of 16 mo and 5 mo and median OS of 27 mo and 9 mo for an SUVmax of greater than 15.0 and an SUVmax of less than or equal to 15.0, respectively, on SSTR PET. In the group with 18F-FDG uptake scored as 3 or 4, the median PFS was 7.1 mo and the median OS was 17.2 mo. In the group with 18F-FDG uptake scored as 0-2, the median PFS was 24.3 mo and the median OS was 41.6 mo. PRRT was well tolerated by all patients; no grade 3 or grade 4 hematotoxicity occurred, and no clinically significant decline in renal function was observed. There was no hepatotoxicity. Conclusion: PRRT was tolerated well, without significant adverse effects, and was efficacious in G3 NENs; the clinical outcome was promising, especially in patients with a Ki-67 index of less than or equal to 55% and even in patients for whom chemotherapy had failed. Baseline 18F-FDG along with SSTR molecular imaging was useful for stratifying G3 NEN patients with high uptake on SSTR PET/CT and no or minor 18F-FDG avidity-a mismatch pattern that was associated with a better long-term prognosis.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhang J, Kulkarni HR, Singh A, et al. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients. J Nucl Med. 2018. PMID: 30115686. doi:10.2967/jnumed.118.215848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。